Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment
Identifieur interne : 000187 ( Main/Exploration ); précédent : 000186; suivant : 000188Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment
Auteurs : Nathan Ford ; Marco Vitoria ; Ajay Rangaraj ; Susan L. Norris ; Alexandra Calmy ; Meg DohertySource :
- Journal of the International AIDS Society [ 1758-2652 ] ; 2020.
Abstract
Several antiretroviral drugs are being considered for the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2). We systematically reviewed the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.
Three databases were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID‐19 treated with antiretrovirals.
From an initial screen of 433 titles, two randomized trials and 24 observational studies provided clinical outcome data on the use of antiretroviral drugs; most studies reported outcomes using LPV/r as treatment. Of the 21 observational studies reporting treatment outcomes, there were three studies among patients with SARS, six studies among patients with MERS and 12 studies among patients with COVID‐19. In one randomized trial 99 patients with severe COVID‐19 illness were randomized to receive LPV/r (400/100 mg twice a day) and 100 patients to standard of care for 14 days: LPV/r was not associated with a statistically significant difference in time to clinical improvement, although LPV/r given within 12 days of symptoms was associated with shorter time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant. The second trial found no benefit. The certainty of the evidence for the randomized trials was low. In the observational studies 3 out of 361 patients who received LPV/r died; the certainty of evidence was very low. Three studies reported a possible protective effect of LPV/r as post‐exposure prophylaxis. Again, the certainty of the evidence was very low due to uncertainty due to limited sample size.
On the basis of the available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes or prevent infection among patients at high risk of acquiring COVID‐19.
Url:
DOI: 10.1002/jia2.25489
PubMed: 32293807
PubMed Central: 7158851
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001839
- to stream Pmc, to step Curation: 001839
- to stream Pmc, to step Checkpoint: 000055
- to stream Ncbi, to step Merge: 003A77
- to stream Ncbi, to step Curation: 003A77
- to stream Ncbi, to step Checkpoint: 003A77
- to stream Main, to step Merge: 000187
- to stream Main, to step Curation: 000187
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment</title>
<author><name sortKey="Ford, Nathan" sort="Ford, Nathan" uniqKey="Ford N" first="Nathan" last="Ford">Nathan Ford</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vitoria, Marco" sort="Vitoria, Marco" uniqKey="Vitoria M" first="Marco" last="Vitoria">Marco Vitoria</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rangaraj, Ajay" sort="Rangaraj, Ajay" uniqKey="Rangaraj A" first="Ajay" last="Rangaraj">Ajay Rangaraj</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Norris, Susan L" sort="Norris, Susan L" uniqKey="Norris S" first="Susan L" last="Norris">Susan L. Norris</name>
<affiliation><nlm:aff id="jia225489-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Calmy, Alexandra" sort="Calmy, Alexandra" uniqKey="Calmy A" first="Alexandra" last="Calmy">Alexandra Calmy</name>
<affiliation><nlm:aff id="jia225489-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Doherty, Meg" sort="Doherty, Meg" uniqKey="Doherty M" first="Meg" last="Doherty">Meg Doherty</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32293807</idno>
<idno type="pmc">7158851</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158851</idno>
<idno type="RBID">PMC:7158851</idno>
<idno type="doi">10.1002/jia2.25489</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">001839</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001839</idno>
<idno type="wicri:Area/Pmc/Curation">001839</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001839</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000055</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000055</idno>
<idno type="wicri:Area/Ncbi/Merge">003A77</idno>
<idno type="wicri:Area/Ncbi/Curation">003A77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A77</idno>
<idno type="wicri:Area/Main/Merge">000187</idno>
<idno type="wicri:Area/Main/Curation">000187</idno>
<idno type="wicri:Area/Main/Exploration">000187</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment</title>
<author><name sortKey="Ford, Nathan" sort="Ford, Nathan" uniqKey="Ford N" first="Nathan" last="Ford">Nathan Ford</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Vitoria, Marco" sort="Vitoria, Marco" uniqKey="Vitoria M" first="Marco" last="Vitoria">Marco Vitoria</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rangaraj, Ajay" sort="Rangaraj, Ajay" uniqKey="Rangaraj A" first="Ajay" last="Rangaraj">Ajay Rangaraj</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Norris, Susan L" sort="Norris, Susan L" uniqKey="Norris S" first="Susan L" last="Norris">Susan L. Norris</name>
<affiliation><nlm:aff id="jia225489-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Calmy, Alexandra" sort="Calmy, Alexandra" uniqKey="Calmy A" first="Alexandra" last="Calmy">Alexandra Calmy</name>
<affiliation><nlm:aff id="jia225489-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Doherty, Meg" sort="Doherty, Meg" uniqKey="Doherty M" first="Meg" last="Doherty">Meg Doherty</name>
<affiliation><nlm:aff id="jia225489-aff-0001"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the International AIDS Society</title>
<idno type="eISSN">1758-2652</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<sec id="jia225489-sec-0001"><title>Introduction</title>
<p>Several antiretroviral drugs are being considered for the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2). We systematically reviewed the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.</p>
</sec>
<sec id="jia225489-sec-0002"><title>Methods</title>
<p>Three databases were screened from inception to 30 March 2020 for studies reporting clinical outcomes of patients with SARS, MERS or COVID‐19 treated with antiretrovirals.</p>
</sec>
<sec id="jia225489-sec-0003"><title>Results</title>
<p>From an initial screen of 433 titles, two randomized trials and 24 observational studies provided clinical outcome data on the use of antiretroviral drugs; most studies reported outcomes using LPV/r as treatment. Of the 21 observational studies reporting treatment outcomes, there were three studies among patients with SARS, six studies among patients with MERS and 12 studies among patients with COVID‐19. In one randomized trial 99 patients with severe COVID‐19 illness were randomized to receive LPV/r (400/100 mg twice a day) and 100 patients to standard of care for 14 days: LPV/r was not associated with a statistically significant difference in time to clinical improvement, although LPV/r given within 12 days of symptoms was associated with shorter time to clinical improvement; 28 day mortality was numerically lower in the LPV/r group (14/99) compared to the control group (25/100), but this difference was not statistically significant. The second trial found no benefit. The certainty of the evidence for the randomized trials was low. In the observational studies 3 out of 361 patients who received LPV/r died; the certainty of evidence was very low. Three studies reported a possible protective effect of LPV/r as post‐exposure prophylaxis. Again, the certainty of the evidence was very low due to uncertainty due to limited sample size.</p>
</sec>
<sec id="jia225489-sec-0004"><title>Conclusions</title>
<p>On the basis of the available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical outcomes or prevent infection among patients at high risk of acquiring COVID‐19.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Calmy, Alexandra" sort="Calmy, Alexandra" uniqKey="Calmy A" first="Alexandra" last="Calmy">Alexandra Calmy</name>
<name sortKey="Doherty, Meg" sort="Doherty, Meg" uniqKey="Doherty M" first="Meg" last="Doherty">Meg Doherty</name>
<name sortKey="Ford, Nathan" sort="Ford, Nathan" uniqKey="Ford N" first="Nathan" last="Ford">Nathan Ford</name>
<name sortKey="Norris, Susan L" sort="Norris, Susan L" uniqKey="Norris S" first="Susan L" last="Norris">Susan L. Norris</name>
<name sortKey="Rangaraj, Ajay" sort="Rangaraj, Ajay" uniqKey="Rangaraj A" first="Ajay" last="Rangaraj">Ajay Rangaraj</name>
<name sortKey="Vitoria, Marco" sort="Vitoria, Marco" uniqKey="Vitoria M" first="Marco" last="Vitoria">Marco Vitoria</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000187 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000187 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:7158851 |texte= Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32293807" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |